jili super ace code
Sir Nick Clegg has warned that Elon Musk risks becoming a “political puppet master” in the United States in a renewed attack on the billionaire businessman. The former UK deputy prime minister, who is second-in-command at Meta, said the Tesla chief executive and X owner had played an “an outsized role” in the US election and in the formation of the new Donald Trump administration. Musk, 53, donated $118 million towards the re-election of Trump and used his social media platform to get behind the Republicans. When asked whether the world’s richest man was a threat to democracy, Clegg told the BBC: “I think Elon Musk is obviously playing an outsized role in both the election and now the formation of the new US administration.
Credit: HCPLive Ophthalmology achieved groundbreaking advancements in 2024, with innovative therapies and cutting-edge technologies reshaping care for some of the most challenging eye conditions. From the US Food and Drug Administration (FDA) approval of the first home optical coherence tomography (OCT) device to advances in gene therapy for neovascular age-related macular degeneration (nAMD) and retinitis pigmentosa, the year brought significant milestones in patient care. Regulatory breakthroughs, including the authorization of autonomous artificial intelligence (AI) for portable diabetic retinopathy screening and the approval of novel therapies like clobetasol propionate eye drops for post-surgical pain, demonstrated a commitment to improving accessibility and outcomes. On the innovation front, new treatment modalities continued to make huge strides. Promising data from trials of RGX-314 and Ixo-vec reinforced the potential of long-term solutions for reducing treatment burden in nAMD, while groundbreaking results for oral gildeuretinol offered hope for slowing geographic atrophy progression. Regulatory shifts, such as the reintroduction of Susvimo and the approval of a prefilled syringe for faricimab, further simplified treatment delivery for retinal diseases. As the year draws to a end, these advancements highlight an exciting future for ophthalmology, with patient-centric approaches driving progress in vision preservation and restoration. On January 16, 2024, Tarsier Pharma received agreement from the FDA under a Special Protocol Assessment (SPA) for the Phase 3 Tarsier-04 trial investigating TRS01 eye drops (Dazdotuftide) for the treatment of non-infectious uveitis, including uveitic glaucoma. The regulatory agency agreed the clinical trial protocol and planned statistical analysis of Phase 3 trial would address objectives supporting regulatory submission. On March 4, 2024, the FDA approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for treating post-operative inflammation and pain following ocular surgery. Awarded to a collaborative team of Formosa Pharmaceuticals and AimMax Therapeutics, clobetasol propionate ophthalmic suspension 0.05% for post-ocular surgery pain marks the first new steroid in the ophthalmic market in over 15 years. Subretinal delivery of ABBV-RGX-314, a potential one-time gene therapy, was well-tolerated without a clinically recognized immune response in the treatment of neovascular (wet) age-related macular degeneration (nAMD) in phase 1/2a trial results. These 2-year data suggested the novel approach of RGX-314 for sustained vascular endothelial growth factor (VEGF)-A suppression could safely maintain vision and reduce treatment burden after a single dose. On April 30, 2024, the FDA cleared the first, fully autonomous artificial intelligence (AI) for portable diabetic retinopathy screening, with the ability to diagnose the disease from retinal images obtained by a handheld camera. Awarded to AEYE Health, the AEYE Diagnostic Screening (AEYE-DS) technology marked the first autonomous AI solution to allow accessible, portable screening using the Optomed Aurora device. Topline results from the Phase 2 PAVIA trial found the vorolanib intravitreal insert (DURAVYUTM) missed its pre-specified primary endpoint, without displaying an improvement of ≥2 Diabetic Retinopathy Severity Scale (DRSS) by week 36. Announced by Eyepoint Pharmaceuticals, the company still reported Duravyu stabilized or improved disease severity with reduced rates of NPDR progression and a favorable safety and tolerability profile. On July 4, 2024, the FDA approved a 6.0 mg single-dose prefilled syringe of faricimab (Vabysmo) for use in the treatment of a trio of ophthalmic disorders, including nAMD, diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Awarded to Genentech, the prefilled syringe is designed to simplify administration and marked the first and only syringe with an FDA-approved bispecific antibody to treat retinal conditions. FDA Accepts sBLA for Susvimo in Treatment of DME, Diabetic Retinopathy On July 8, 2024, Genentech/Roche has signaled the reintroduction of Susvimo® (ranibizumab injection) 100 mg/mL for intravitreal use via an ocular implant for neovascular (wet) age-related macular degeneration (nAMD), marking the end of a voluntary recall. The FDA granted a post-approval supplement to the Biologics License Application for Susvimo based on component-level updates to the ocular implant and refill needle. Later that month, on July 18, 2024, the FDA accepted the supplemental BLA (sBLA) for Susvimo for the treatment of DME and diabetic retinopathy. The filing was accepted based on the 1-year study results from the Phase 3 Pagoda and Pavilion studies, with both studies meeting their primary endpoints of non-inferior visual acuity gains from baseline to monthly ranibizumab and superior improvements on the Diabetic Retinopathy Severity Scale (DRSS) to clinical observation, respectively. On September 17, 2024, Alkeus Pharmaceuticals announced oral gildeuretinol acetate (ALK-001) achieved a clinically meaningful reduction in geographic atrophy (GA) lesion growth at 24 months in patients with GA secondary to AMD. Gildeuretinol, a novel molecule created as a specialized form of deuterated Vitamin A, also achieved a statistically significant slowing of low-luminance visual acuity (LLVA) decline at 24 months, with a favorable safety and tolerability profile in patients with GA. On October 9, 2024, Clearside Biomedical announced axitinib injectable suspension (CLS-AX) achieved all primary and secondary outcomes in the treatment of nAMD in the Phase 2b ODYSSEY trial. Suprachoroidal CLS-AX demonstrated stability in visual acuity and anatomical control for up to 6 months, with a well-tolerated safety profile without ocular or treatment-related serious adverse events (SAEs). On October 3, 2024, Aldeyra Therapeutics resubmitted a New Drug Application (NDA) to the FDA for their investigational new drug candidate, topical ocular reproxalap, for the treatment of signs and symptoms of dry eye disease (DED). The resubmitted NDA for reproxalap included positive results from a recently finished Phase 3 DED symptom trial requested by the FDA after a Complete Response Letter (CRL) received in Novemebr 2023. The resubmitted NDA also involved a draft label reflecting acute activity in reducing dry eye symptoms in a dry eye chamber trial, chronic activity in reducing dry eye symptoms in a field trial, and acute activity in reducing ocular redness in two dry eye chamber trials. RESTORE: MCO-010 Achieves Significant Vision Restoration in Retinitis Pigmentosa On October 10, 2024, Nanoscope Therapeutics announced plans to submit the Biologics License Application (BLA) for MCO-010 gene therapy for the treatment of severe vision loss due to retinitis pigmentosa in the first quarter of 2025. The announcement followed a productive meeting with the FDA discussing the MCO-010 clinical trial program with the agency acknowledging the company’s proposal for the next steps for submission. Earlier in the year, positive topline results from the 2-year Phase 2b RESTORE trial showed statistically significant and clinically meaningful improvement in best-corrected visual acuity (BCVA) with MCO-010 in patients with permanent and severe vision loss from advanced retinitis pigmentosa. On November 15, 2024, the FDA issued a CRL for the supplemental New Drug Application (sNDA) of avacincaptad pegol intravitreal solution (IZERVAY) for the treatment of GA secondary to AMD. Announced by Astellas Pharma, the sNDA was intended to include new positive Phase 3 2-year data from the GATHER2 trial in the US prescribing information. Intended for a decision by its Prescription Drug User Fee Act (PDUFA) target action date of November 19, 2024, the FDA indicated it cannot approve the sNDA in its present form, owing to comments on a statistical matter related to labeling language proposed by Astellas. The agency outlined no comments on the safety or benefit-risk profile of avacincaptad pegol for GA secondary to AMD. On November 18, 2024, Alkeus Pharmaceuticals announced gildeuretinol (ALK-001), an investigational oral therapy, received Rare Pediatric Disease and Fast Track designations from the FDA for the treatment of Stargardt disease. The company indicated its plans to apply for a Priority Review voucher with the submission of the NDA for gildeuretinol for Stargardt. On November 18, 2024, Adverum Biotechnologies announced topline 1-year results from the LUNA Phase 2 trial and 4-year follow-up of the OPTIC first-in-human trial. These data supported the long-term potential of intravitreal ixoberogene soroparvovec (Ixo-vec) gene therapy for patients with nAMD, with 52-week efficacy data on the 6E10 dose and 4-year data on the 2E11 dose demonstrating maintenance of visual and anatomic endpoints, with an ≥80% reduction in injection burden and ≥50% injection freedom. Traditional optical coherence tomography (OCT) devices require a patient with retinal diseases to visit an office, an often time-consuming task, and there is a delay between scans which can lead to disease progression. In May 2024, the FDA granted De Novo authorization to Notal Vision’s patient self-operated home OCT product, Scanly, for the monitoring of retinal diseases at home, including nAMD. In our This Year in Medicine feature, we take a look at how the device could provide eye care professionals unprecedented insight into how treatments work in real-time, empowering patients to take a more active role in preserving their vision.
Stock market today: Wall Street gains ground as it notches a winning week and another Dow record
After a long and winding journey, three-star quarterback Bekkem Kritza finally signed with Penn State. Kritza, the No. 37 quarterback in the country, committed to Penn State on Nov. 11, 2023, as one of the longest-tenured commitments in this 2025 class. As the only quarterback in Penn State’s class as of now, he visited campus 12 times over the years. The QB was Penn State’s 13th signee on signing day Wednesday. At 6-foot-5 and 195 pounds, Kritza hailed from Colorado when he made the commitment to Penn State, but he moved back home to Florida for his senior season and started the year at Miami Central. He lost the starting quarterback job at Miami Central and wound up transferring to Chaminade-Madonna Prep midseason, where he led an upset win over St. Thomas Aquinas in his early October debut. Despite the adversity-filled path to becoming a Lion, things have worked out for Kritza. He’ll be leading Chaminade-Madonna in the state semifinals this weekend against Trinity Christian Academy. He’s a talented thrower of the football who has struggled with accuracy at times, but coach James Franklin was excited to get Kritza officially on this recruiting class. “Once you get on campus, we’ll be there to support you every step of the way,” Franklin said Wednesday. “It’s not always going to be easy. It’ll be challenging. But you’re built for that, and it’s going to be awesome to watch you grow and thrive here under the Penn State umbrella.” All-time Penn State passing leader Sean Clifford, currently with the Green Bay Packers, welcomed Kritza to Happy Valley. “Welcome to the Penn State family,” Clifford said. “Can’t wait to see you become the next great Penn State quarterback.” Penn State signed 26 players Wednesday, including five from WPIAL schools — Imani Christian defensive lineman Dayshaun Burnett, Aliquippa running back Tikey Hayes, North Catholic offensive lineman Brady O’Hara, Latrobe linebacker Alex Tatsch and Central Catholic defensive back Xxavier Thomas. Burnett, a four-star and the No. 11 player in Pennsylvania, is expected to become an edge rusher. Franklin called Hayes, a three-star prospect and the No. 12 player in Pennsylvania, one of the more underappreciated running backs in the country. He is also the nephew of cornerbacks coach/associate head coach Terry Smith, who leads Penn State ’s recruiting efforts in the Pittsburgh area. Originally recruited as a tight end, O’Hara will enroll as an offensive lineman. He’s a three-star and the No. 15 player in Pennsylvania. Tatsch, a four-star recruit and No. 7 player in Pennsylvania, had an injury that limited him to five games this year but is expected to be a big part of the future linebacking corps. Thomas visited Penn State 17 times and never went anywhere else in the process, according to On3. He’s ranked as a three-star prospect and the No. 14 player in Pennsylvania. Another notable signing was LaVar Arrington II, the son of “Linebacker U” legend LaVar Arrington. He is a four-star linebacker from Charter Oak High School (Calif.). Arrington is ranked as high as the No. 9 linebacker and the No. 127 overall prospect in the 2025 recruiting cycle, according to 247 Sports. The elder Arrington was a two-time first-team All-American who racked up 173 tackles, 39 tackles for loss and 19 sacks in his Penn State career. Arrington was inducted into the College Football Hall of Fame in 2022. Penn State signed 23 recruits who were rated four stars or higher by 247Sports, On3, ESPN or Rivals. The class has players from 10 different states. There are 13 offensive players and 13 defensive players.The standard Lorem Ipsum passage, used since the 1500s "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" Thanks for your interest in Kalkine Media's content! To continue reading, please log in to your account or create your free account with us.
Kevin Kisner, a four-time winner on the PGA Tour, was named lead analyst for NBC Sports' golf coverage alongside commentator Dan Hicks. Kisner, 40, made his debut as an analyst for NBC in 2024, working in the booth for the Phoenix Open, The Players Championship and the FedEx Cup Playoffs. A native of Aiken, S.C., Kisner still will maintain a limited playing schedule on the PGA Tour. He participated in 23 events in 2004 and made the cut six times, while finishing 198th in the FedEx Cup points standings. "I'm humbled and grateful to have the chance to sit in the seat that many legends like Johnny Miller and Paul Azinger have sat in before me on NBC," Kisner said in a release. "I'm looking forward to offering a different voice and adding a new dynamic to the broadcasts, hopefully reaching more fans and telling things like it is. That's what I think I do best." Kisner's most recent PGA Tour victory came in the 2021 Wyndham Championship when he bested Branden Grace, Si-woo Kim, Kevin Na, Adam Scott and Roger Sloan in a playoff. Kisner also earned wins at the 2019 WGC-Dell Technologies Match Play, the 2017 Dean & DeLuca Invitational and the 2015 RSM Classic. He has earned $29.3 million since first joining the tour in 2011. This article first appeared on Field Level Media and was syndicated with permission.B.C. Conservative leader faces test after colleagues' letter attacks Surrey MLAPaklap's Guide to the Best Productivity-Enhancing Tech GadgetsDec. 29—From here on out, it gets real for the Washington men's basketball team. That's not to suggest the first two months of the season didn't matter, but the caliber of opponents will exponentially increase for the Huskies, who clobbered New Jersey Institute of Technology (NJIT) 90-53 on Sunday afternoon in their nonconference finale. "There's a lot of times this program — and a lot of programs — haven't won nine games all year. Let's not forget that," coach Danny Sprinkle said noting UW's 9-4 overall record and 0-2 mark in the Big Ten. "This team being a brand-new team, that's a hell of a nonconference for these guys ... to be 9-4 before New Year's. That's a heck of a job by this team and by my staff. I'm not taking any credit for it. "We've beaten some really good teams in Colorado State, Santa Clara and Washington State. ... I don't know if I've given our team enough credit or confidence for winning those games, because you kind of go in as a coach like expecting to play really well and to win those games. But I also have to be a realist too." The Huskies desperately wanted to end the nonconference portion of their schedule on a high note and the Highlanders (2-12), who have lost 14 straight road games, were overmatched and undermanned against Washington, which executed a flawless paint-by-numbers performance in front of 6,779 at Alaska Airlines Arena. The largest blowout of the season for UW allowed Sprinkle to rest starters, empty the bench and get a long look at seldom-used reserves. The Huskies also welcomed back senior forward Wilhelm Breidenbach who finished with 10 points and five rebounds in his first outing since sustaining a concussion on Dec. 18. "I was having symptoms right after and I couldn't play in our last game and was just getting back into practice," said Breidenbach who converted 3 of 4 shots, including two 3-pointers. "But it's been fine. It's a good group of guys, so it's easy to easy to get back into the group." Washington missed Breidenbach during its previous game when they lost 79-70 to Seattle U and was outrebounded 36-33. "We're totally different and you can see how much we missed him against Seattle U," Sprinkle said. "Everything flows better with him in the game. We're a more normal team offensively, and then defensively we're way better because he knows coverages. He's played a lot of basketball. He rebounds and his size." Forward Great Osobor added: "He just changes us in a way, like he's one of our highest IQ players and he's 6-10. He just makes reads that come natural to him. ... It's stuff you can't teach he does, and he just makes us a better team." Before his earliest departure of the season, Osobor, who had team-high tying 12 points and six rebounds in 17 minutes, connected on his first three-pointer of the season after missing eight attempts. Osobor also orchestrated the game's biggest highlight when he pushed the pace on a fast break and delivered a pass through a thicket of defenders to a streaking Tyler Harris who flushed a crowd-pleading two-hand dunk for a 58-30 lead with 15:52 left. "When I got the rebound, my mind says, 'Just go'," Osobor said. "It's just natural for me and I've been doing it my whole life. ... I see Tyler rim running. I'd already had one or two turnovers at that point, and the gap was kind of tight. "Then I thought, 'Is this a bad pass?' Maybe and then I just threw anyway and it got to where it needed to go and Tyler did the rest." Speaking of firsts, backup center KC Ibeweke, who appeared in just four games before Sunday, scored for the first time and finished with nine points on 3-for-5 shooting in 16 minutes. "I thought he played hard," Sprinkle said. "He did a really good job in ball screen defense. He did a lot of stuff the casual fan, they have no idea because they don't know what we're supposed to do defensively. "He executed all those and I'm proud of him, because we're going to need him. We're going to need his size and his girth, In Big Ten play, he's got to play meaningful minutes for us." Following a sporadic start, it took Washington about 10 minutes to seize control. After Osobor spun free for a layup, guard Tyree Ihenacho drove to the rim for a basket and collected a steal for a fastbreak layup that capped a 6-0 run, which put UW up 32-18 with 6:30 left in the first half. Minutes later, freshman guard Jase Butler drained an open 3-pointer off a feed from Butler that gave the Huskies a 42-22 lead just before the break. Washington led 46-26 at halftime and outscored NJIT 44-27 in the second half thanks in large part to freshman guard Zoom Diallo who finished with a career-high five assists and had 10 of his 12 points after the intermission. Sebastian Robinson had 16 points, Tim Moore 14 and Ari Fulton 11 for the Highlanders, which shot 37.3% from the field and converted 3 of 17 three-pointers. Meanwhile, Washington shot 55.7% on field goals, including 10 of 24 on 3-pointers and converted 12 of 14 free throws. The Huskies has more rebounds (33-29), assists (21-5), steals (12-2), bench points (47-4) and fewer turnovers (5-13). "We didn't get sloppy today," Sprinkle said. "Sometimes in those games, you can get sloppy and guys try to do too much, but I thought we did a great job sharing the basketball and only had five turnovers. ... When we're passing the ball well and making the extra pass, those are the games where we go 10 of 24 from three." Immediately after the game, the Huskies began preparing for Thursday's pivotal matchup at home against Maryland (11-2, 1-1), which starts an 18-game trek through the Big Ten. "As a staff, we'll get going tonight," Sprinkle said. "I want our guys to get away, relax, get some treatment and enjoy this win. Like I said, winning at this level is hard. You have to be able to enjoy it. But once midnight hits, we got to, we got to turn our attention to Maryland." The Terrapins are ranked 10th in the NET and have rarely been tested while outscoring opponents by 26.2 points, which is tops among Division I teams. Maryland boasts a high-powered offense that ranks 10th in the country in scoring (87.2 points per game) as well as a resilient defense that's 13th nationally in points allowed (61.1). "Obviously, it's great team coming in," Osobor said. "We already know they've been killing it all year and it's exciting. It's why you come to Washington. So, I'm excited. "I feel like our team, we've had ups and downs, but one thing is, we've learned each game is who we are. And as long as we can keep establishing our identity and doing things we want to do, then I think we'll take it head on and handle these game one game at a time." Notes: — UW fifth-year center Franck Kepnang who has played two games this season due to a knee injury is expected to return in 2-3 weeks, Sprinkle said. — UW freshman forward Dominique Diomonde, who signed last week, is overseas and waiting for a visa, which would allow him to travel to Seattle and play for the Huskies. "I wish I knew an exact date," Sprinkle said. "It could be tomorrow he gets on a plane or it could be in two weeks. It just depends when the embassy over there give him his visa." BOX SCORE (c)2024 The Seattle Times Visit The Seattle Times at www.seattletimes.com Distributed by Tribune Content Agency, LLC.